{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T12:14:26Z","timestamp":1787919266925,"version":"build-2784847793"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T00:00:00Z","timestamp":1712188800000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100019944","name":"Sanofi-Aventis Deutschland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019944","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s40121-024-00958-7","type":"journal-article","created":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T04:02:39Z","timestamp":1712203359000},"page":"907-920","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Modelling the Public Health Impact of MenACWY and MenC Adolescent Vaccination Strategies in Germany"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5291-650X","authenticated-orcid":false,"given":"Sebastian","family":"Gruhn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4445-965X","authenticated-orcid":false,"given":"Manuel","family":"Batram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3032-6354","authenticated-orcid":false,"given":"Moritz","family":"Wick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith","family":"Langevin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8421-8829","authenticated-orcid":false,"given":"Stefan","family":"Scholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9552-6969","authenticated-orcid":false,"given":"Wolfgang","family":"Greiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0261-3655","authenticated-orcid":false,"given":"Oliver","family":"Damm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,4]]},"reference":[{"key":"958_CR1","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S1473-3099(10)70251-6","volume":"10","author":"H Christensen","year":"2010","unstructured":"Christensen H, May M, Bowen L, et\u00a0al. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10:853\u201361. https:\/\/doi.org\/10.1016\/S1473-3099(10)70251-6.","journal-title":"Lancet Infect Dis"},{"key":"958_CR2","doi-asserted-by":"publisher","unstructured":"Nuttens C, Findlow J, Balmer P et al. Evolution of invasive meningococcal disease epidemiology in Europe, 2008 to 2017. Euro Surveill. 2022. https:\/\/doi.org\/10.2807\/1560-7917.ES.2022.27.3.2002075.","DOI":"10.2807\/1560-7917.ES.2022.27.3.2002075"},{"key":"958_CR3","doi-asserted-by":"publisher","unstructured":"Krone M, Gray S, Abad R et al. Increase of invasive meningococcal serogroup W disease in Europe, 2013 to 2017. Euro Surveill. 2019. https:\/\/doi.org\/10.2807\/1560-7917.ES.2019.24.14.1800245.","DOI":"10.2807\/1560-7917.ES.2019.24.14.1800245"},{"key":"958_CR4","doi-asserted-by":"publisher","first-page":"1000657","DOI":"10.3389\/fped.2022.1000657","volume":"10","author":"G Pinto Cardoso","year":"2022","unstructured":"Pinto Cardoso G, Lagr\u00e9e-Chastan M, Caseris M, et\u00a0al. Overview of meningococcal epidemiology and national immunization programs in children and adolescents in 8 Western European countries. Front Pediatr. 2022;10:1000657. https:\/\/doi.org\/10.3389\/fped.2022.1000657.","journal-title":"Front Pediatr"},{"key":"958_CR5","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/20477724.2021.1972663","volume":"116","author":"F Martin\u00f3n-Torres","year":"2022","unstructured":"Martin\u00f3n-Torres F, Taha M-K, Knuf M, et\u00a0al. Evolving strategies for meningococcal vaccination in Europe: overview and key determinants for current and future considerations. Pathog Glob Health. 2022;116:85\u201398. https:\/\/doi.org\/10.1080\/20477724.2021.1972663.","journal-title":"Pathog Glob Health"},{"key":"958_CR6","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S2352-4642(21)00335-7","volume":"6","author":"H Campbell","year":"2022","unstructured":"Campbell H, Andrews N, Parikh SR, et\u00a0al. Impact of an adolescent meningococcal ACWY immunisation programme to control a national outbreak of group W meningococcal disease in England: a national surveillance and modelling study. Lancet Child Adolesc Health. 2022;6:96\u2013105. https:\/\/doi.org\/10.1016\/S2352-4642(21)00335-7.","journal-title":"Lancet Child Adolesc Health"},{"key":"958_CR7","doi-asserted-by":"publisher","first-page":"1649.e1","DOI":"10.1016\/j.cmi.2022.07.004","volume":"28","author":"JP Carr","year":"2022","unstructured":"Carr JP, MacLennan JM, Plested E, et\u00a0al. Impact of meningococcal ACWY conjugate vaccines on pharyngeal carriage in adolescents: evidence for herd protection from the UK MenACWY programme. Clin Microbiol Infect. 2022;28:1649.e1-1649.e8. https:\/\/doi.org\/10.1016\/j.cmi.2022.07.004.","journal-title":"Clin Microbiol Infect"},{"key":"958_CR8","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1093\/cid\/ciab791","volume":"74","author":"M Ohm","year":"2022","unstructured":"Ohm M, Hahn\u00e9 SJM, van der Ende A, et\u00a0al. Vaccine impact and effectiveness of meningococcal serogroup ACWY conjugate vaccine implementation in the Netherlands: a nationwide surveillance study. Clin Infect Dis. 2022;74:2173\u201380. https:\/\/doi.org\/10.1093\/cid\/ciab791.","journal-title":"Clin Infect Dis"},{"key":"958_CR9","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1016\/j.vaccine.2022.02.043","volume":"40","author":"S Gruhn","year":"2022","unstructured":"Gruhn S, Witte J, Greiner W, et\u00a0al. Epidemiology and economic burden of meningococcal disease in Germany: a systematic review. Vaccine. 2022;40:1932\u201347. https:\/\/doi.org\/10.1016\/j.vaccine.2022.02.043.","journal-title":"Vaccine"},{"key":"958_CR10","doi-asserted-by":"publisher","unstructured":"Robert Koch-Institut. Empfehlung zur Standardimpfung von S\u00e4uglingen gegen Meningokokken der Serogruppe B und die dazugeh\u00f6rige wissenschaftliche Begr\u00fcndung. 2024. https:\/\/doi.org\/10.25646\/11900.","DOI":"10.25646\/11900"},{"key":"958_CR11","unstructured":"Robert Koch-Institut. Infektionsepidemiologisches Jahrbuch meldepflichtiger Krankheiten f\u00fcr 2018. Robert Koch-Institut. 2019."},{"key":"958_CR12","unstructured":"Statistisches Bundesamt. Bev\u00f6lkerung im Wandel: Annahmen und Ergebnisse der 14. Koordinierten Bev\u00f6lkerungsvorausberechnung. 2019."},{"key":"958_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0050074","volume":"5","author":"J Mossong","year":"2008","unstructured":"Mossong J, Hens N, Jit M, et\u00a0al. Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Med. 2008;5: e74. https:\/\/doi.org\/10.1371\/journal.pmed.0050074.","journal-title":"PLoS Med"},{"key":"958_CR14","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1186\/s12916-021-02139-6","volume":"19","author":"DV Tomori","year":"2021","unstructured":"Tomori DV, R\u00fcbsamen N, Berger T, et\u00a0al. Individual social contact data and population mobility data as early markers of SARS-CoV-2 transmission dynamics during the first wave in Germany\u2014an analysis based on the COVIMOD study. BMC Med. 2021;19:271. https:\/\/doi.org\/10.1186\/s12916-021-02139-6.","journal-title":"BMC Med"},{"key":"958_CR15","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1016\/j.vaccine.2013.03.034","volume":"31","author":"H Christensen","year":"2013","unstructured":"Christensen H, Hickman M, Edmunds WJ, et\u00a0al. Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact. Vaccine. 2013;31:2638\u201346. https:\/\/doi.org\/10.1016\/j.vaccine.2013.03.034.","journal-title":"Vaccine"},{"key":"958_CR16","doi-asserted-by":"publisher","first-page":"7558","DOI":"10.1016\/j.vaccine.2020.08.007","volume":"38","author":"E Beck","year":"2020","unstructured":"Beck E, Klint J, Garcia S, et\u00a0al. Modelling the impact of 4CMenB and MenACWY meningococcal combined vaccination strategies including potential 4CMenB cross-protection: an application to England. Vaccine. 2020;38:7558\u201368. https:\/\/doi.org\/10.1016\/j.vaccine.2020.08.007.","journal-title":"Vaccine"},{"key":"958_CR17","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1086\/428590","volume":"191","author":"H Claus","year":"2005","unstructured":"Claus H, Maiden MCJ, Wilson DJ, et\u00a0al. Genetic analysis of meningococci carried by children and young adults. J Infect Dis. 2005;191:1263\u201371. https:\/\/doi.org\/10.1086\/428590.","journal-title":"J Infect Dis"},{"key":"958_CR18","unstructured":"Robert Koch-Institut SurvStat@RKI 2.0: Web-basierte Abfrage der Meldedaten gem\u00e4\u00df Infektionsschutzgesetz (IfSG)."},{"key":"958_CR19","unstructured":"Robert Koch-Institut. \"Invasive Meningokokken- Erkrankungen 2012\u2009\u2013\u20092015\". RKI-Bib1 (Robert Koch-Institut). 2016."},{"key":"958_CR20","unstructured":"Robert Koch-Institut. Infektionsepidemiologisches Jahrbuch meldepflichtiger Krankheiten f\u00fcr 2016. Robert Koch-Institut. 2017."},{"key":"958_CR21","unstructured":"Robert Koch-Institut. Infektionsepidemiologisches Jahrbuch meldepflichtiger Krankheiten f\u00fcr 2017. Robert Koch-Institut. 2018."},{"key":"958_CR22","unstructured":"Robert Koch-Institut. Infektionsepidemiologisches Jahrbuch meldepflichtiger Krankheiten f\u00fcr 2019. Robert Koch-Institut. 2020."},{"key":"958_CR23","unstructured":"Robert Koch-Institut. Infektionsepidemiologischse Jahrbuch meldepflichtiger Krankheiten f\u00fcr 2020. Robert Koch-Institut. 2021."},{"key":"958_CR24","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jinf.2012.09.008","volume":"66","author":"W Hellenbrand","year":"2013","unstructured":"Hellenbrand W, Elias J, Wichmann O, et\u00a0al. Epidemiology of invasive meningococcal disease in Germany, 2002\u20132010, and impact of vaccination with meningococcal C conjugate vaccine. J Infect. 2013;66:48\u201356. https:\/\/doi.org\/10.1016\/j.jinf.2012.09.008.","journal-title":"J Infect"},{"key":"958_CR25","unstructured":"Statistisches Bundesamt. Sterbetafeln. 2023. https:\/\/www-genesis.destatis.de\/genesis\/online?sequenz=statistikTabellen&selectionname=12621."},{"key":"958_CR26","unstructured":"Rieck T, Feig M, Siedler A. Impfquoten von Kinderschutzimpfungen in Deutschland\u2014aktuelle Ergebnisse aus der RKI-Impfsurveillance. Epidemiol Bull. 2022;3\u201325."},{"key":"958_CR27","unstructured":"Rieck T. KV-Impfsurveillance\u2014M\u00f6glichkeiten und Herausforderungen der Analyse der KV-Daten. 2019."},{"key":"958_CR28","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1128\/CVI.00529-09","volume":"17","author":"H Campbell","year":"2010","unstructured":"Campbell H, Andrews N, Borrow R, et\u00a0al. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol. 2010;17:840\u20137. https:\/\/doi.org\/10.1128\/CVI.00529-09.","journal-title":"Clin Vaccine Immunol"},{"key":"958_CR29","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1086\/527401","volume":"197","author":"MCJ Maiden","year":"2008","unstructured":"Maiden MCJ, Ibarz-Pav\u00f3n AB, Urwin R, et\u00a0al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis. 2008;197:737\u201343. https:\/\/doi.org\/10.1086\/527401.","journal-title":"J Infect Dis"},{"key":"958_CR30","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1016\/S0140-6736(14)60842-4","volume":"384","author":"RC Read","year":"2014","unstructured":"Read RC, Baxter D, Chadwick DR, et\u00a0al. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. Lancet. 2014;384:2123\u201331. https:\/\/doi.org\/10.1016\/S0140-6736(14)60842-4.","journal-title":"Lancet"},{"key":"958_CR31","doi-asserted-by":"publisher","unstructured":"Cohn AC, MacNeil JR, Harrison LH et al. Effectiveness and duration of protection of one dose of a meningococcal conjugate vaccine. Pediatrics. 2017;139:e20162193. https:\/\/doi.org\/10.1542\/peds.2016-2193.","DOI":"10.1542\/peds.2016-2193"},{"key":"958_CR32","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1745-6673-8-4","volume":"8","author":"J Elias","year":"2013","unstructured":"Elias J, Findlow J, Borrow R, et\u00a0al. Persistence of antibodies in laboratory staff immunized with quadrivalent meningococcal polysaccharide vaccine. J Occup Med Toxicol. 2013;8:4. https:\/\/doi.org\/10.1186\/1745-6673-8-4.","journal-title":"J Occup Med Toxicol"},{"key":"958_CR33","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1093\/aje\/kwi160","volume":"162","author":"CL Trotter","year":"2005","unstructured":"Trotter CL, Gay NJ, Edmunds WJ. Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination. Am J Epidemiol. 2005;162:89\u2013100. https:\/\/doi.org\/10.1093\/aje\/kwi160.","journal-title":"Am J Epidemiol"},{"key":"958_CR34","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1056\/NEJMoa1900236","volume":"382","author":"HS Marshall","year":"2020","unstructured":"Marshall HS, McMillan M, Koehler AP, et\u00a0al. Meningococcal B vaccine and meningococcal carriage in adolescents in Australia. N Engl J Med. 2020;382:318\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1900236.","journal-title":"N Engl J Med"},{"key":"958_CR35","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1007\/s00103-015-2253-z","volume":"58","author":"W Hellenbrand","year":"2015","unstructured":"Hellenbrand W, Koch J, Harder T, et\u00a0al. Background Paper for the update of meningococcal vaccination recommendations in Germany: use of the serogroup B vaccine in persons at increased risk for meningococcal disease. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2015;58:1314\u201343. https:\/\/doi.org\/10.1007\/s00103-015-2253-z.","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"958_CR36","unstructured":"St\u00e4ndige Impfkommission. Stellungnahme der St\u00e4ndigen Impfkommission (STIKO) am Robert Koch-Institut (RKI) zum Stand der Bewertung des neuen Meningokokken-B-Impfstoffs Bexsero\u00ae. Epidemiol Bull. 2013;495\u2013504."},{"key":"958_CR37","unstructured":"St\u00e4ndige Impfkommission. Aktualisierte Stellungnahme der St\u00e4ndigen Impfkommission (STIKO) am Robert Koch-Institut (RKI). Epidemiol Bull. 2018;5\u201344."},{"key":"958_CR38","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s40121-021-00573-w","volume":"11","author":"S Scholz","year":"2022","unstructured":"Scholz S, Schwarz M, Beck E, et\u00a0al. Public health impact and cost-effectiveness analysis of routine infant 4CMenB vaccination in Germany to prevent serogroup B invasive meningococcal disease. Infect Dis Ther. 2022;11:367\u201387. https:\/\/doi.org\/10.1007\/s40121-021-00573-w.","journal-title":"Infect Dis Ther"},{"key":"958_CR39","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1056\/NEJMoa1901229","volume":"382","author":"SN Ladhani","year":"2020","unstructured":"Ladhani SN, Andrews N, Parikh SR, et\u00a0al. Vaccination of infants with meningococcal group B Vaccine (4CMenB) in England. N Engl J Med. 2020;382:309\u201317. https:\/\/doi.org\/10.1056\/NEJMoa1901229.","journal-title":"N Engl J Med"},{"key":"958_CR40","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/S1473-3099(13)70006-9","volume":"13","author":"U Vogel","year":"2013","unstructured":"Vogel U, Taha M-K, Vazquez JA, et\u00a0al. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis. 2013;13:416\u201325. https:\/\/doi.org\/10.1016\/S1473-3099(13)70006-9.","journal-title":"Lancet Infect Dis"},{"key":"958_CR41","unstructured":"Johnson SG. The NLopt nonlinear-optimization package. 2014."},{"key":"958_CR42","unstructured":"Robert CP. The Metropolis\u2013Hastings algorithm. 2016."},{"key":"958_CR43","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3758\/s13423-016-1015-8","volume":"25","author":"D van Ravenzwaaij","year":"2018","unstructured":"van Ravenzwaaij D, Cassey P, Brown SD. A simple introduction to Markov Chain Monte-Carlo sampling. Psychon Bull Rev. 2018;25:143\u201354. https:\/\/doi.org\/10.3758\/s13423-016-1015-8.","journal-title":"Psychon Bull Rev"},{"key":"958_CR44","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1016\/j.vaccine.2016.04.004","volume":"34","author":"H Christensen","year":"2016","unstructured":"Christensen H, Irving T, Koch J, et\u00a0al. Epidemiological impact and cost-effectiveness of universal vaccination with Bexsero(\u00ae) to reduce meningococcal group B disease in Germany. Vaccine. 2016;34:3412\u20139. https:\/\/doi.org\/10.1016\/j.vaccine.2016.04.004.","journal-title":"Vaccine"},{"key":"958_CR45","doi-asserted-by":"publisher","unstructured":"Ohm M, van Rooijen DM, Bona\u010di\u0107 Marinovi\u0107 AA et al. Different long-term duration of seroprotection against Neisseria meningitidis in adolescents and middle-aged adults after a single meningococcal ACWY conjugate vaccination in The Netherlands. Vaccines. 2020;8:624. https:\/\/doi.org\/10.3390\/vaccines8040624.","DOI":"10.3390\/vaccines8040624"},{"key":"958_CR46","unstructured":"Sch\u00f6nfeld V, Pozo Martin F, Scholz S et\u00a0al. Auffrischimpfung gegen Meningokokken der Serogruppe C (AMSeC): Absch\u00e4tzung der Effekte auf Krankheitslast und Kosten im deutschen Gesundheitssystem: Vorstellung der Studie, DGKJ\u2014Kongress f\u00fcr Kinder- und Jugendmedizin, M\u00fcnchen. 2019."},{"key":"958_CR47","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.vaccine.2013.09.034","volume":"33","author":"DM Vickers","year":"2015","unstructured":"Vickers DM, Anonychuk AM, de Wals P, et\u00a0al. Evaluation of serogroup C and ACWY meningococcal vaccine programs: projected impact on disease burden according to a stochastic two-strain dynamic model. Vaccine. 2015;33:268\u201375. https:\/\/doi.org\/10.1016\/j.vaccine.2013.09.034.","journal-title":"Vaccine"},{"key":"958_CR48","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.jinf.2020.05.079","volume":"81","author":"SR Parikh","year":"2020","unstructured":"Parikh SR, Campbell H, Bettinger JA, et\u00a0al. The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination. J Infect. 2020;81:483\u201398. https:\/\/doi.org\/10.1016\/j.jinf.2020.05.079.","journal-title":"J Infect"},{"key":"958_CR49","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268823000328","volume":"151","author":"C Pardo de Santayana","year":"2023","unstructured":"Pardo de Santayana C, Tin Tin Htar M, Findlow J, et\u00a0al. Epidemiology of invasive meningococcal disease worldwide from 2010\u20132019: a literature review. Epidemiol Infect. 2023;151: e57. https:\/\/doi.org\/10.1017\/S0950268823000328.","journal-title":"Epidemiol Infect"},{"key":"958_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/S2589-7500(23)00108-5","author":"D Shaw","year":"2023","unstructured":"Shaw D, Abad R, Amin-Chowdhury Z, et\u00a0al. Trends in invasive bacterial diseases during the first 2 years of the COVID-19 pandemic: analyses of prospective surveillance data from 30 countries and territories in the IRIS Consortium. Lancet Digit Health. 2023. https:\/\/doi.org\/10.1016\/S2589-7500(23)00108-5.","journal-title":"Lancet Digit Health"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-024-00958-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-024-00958-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-024-00958-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T13:26:29Z","timestamp":1714397189000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-024-00958-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["958"],"URL":"https:\/\/doi.org\/10.1007\/s40121-024-00958-7","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"13 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Moritz Wick, Edith Langevin and Oliver Damm are Sanofi employees and may hold shares and\/or stock options in the company. Sebastian Gruhn, Manuel Batram, Stefan Scholz and Wolfgang Greiner received research grants from Sanofi-Aventis Deutschland GmbH. All authors declare no other financial or nonfinancial relationships and activities. Stefan Scholz has changed affiliation after the completion of the manuscript and is now an employee of Moderna Germany GmbH.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}